cutaneous melanomaacralmucosalmetastatic melanomagenetic predisposition melanoma risk factorsgenes MC1RCDKN2ACDK4MITF“driver” genes BRAFNRASKITgenes PPP6CRAC1TACCnevi malignizationmelanoma targeted therapyмеланома кожиакральнаямукозальнаяметастазирующая меланоманаследственные факторы риска меланомыгены MC1RCDKN2ACDK4MITFмутации генов BRAFNRASKITгены PPP6CRAC1TACC1малигнизация невусовтаргетная терапия меланомы1.1. Bertolotto C. Melanoma: from melanocyte to genetic alterations and clinical options. Scientifica 2013;2013:635203.Bertolotto C. Melanoma: from melanocyte to genetic alterations and clinical options. Scientifica 2013;2013:635203.2.2. Статистика злокачественных новообразований в России и странах СНГ в 2012 году. Под ред. М. И. Давыдова, Е. М. Аксель. М., 2014. 226 с. [Statistics of malignant neoplasms in russia and the CIS countries in 2012. M.I. Davydov, E.M. Axel (eds.). Moscow, 2014. 226 p. (In Russ.)]Статистика злокачественных новообразований в России и странах СНГ в 2012 году. Под ред. М. И. Давыдова, Е. М. Аксель. М., 2014. 226 с. [Statistics of malignant neoplasms in russia and the CIS countries in 2012. M.I. Davydov, E.M. Axel (eds.). Moscow, 2014. 226 p. (In Russ.)]3.3. MаcKie R.M., Hauschild A., Eggermont A. M. Epidemiology of invasive cutaneous melanoma. Ann Oncol 2009;20 Suppl 6:vi1–7.MаcKie R.M., Hauschild A., Eggermont A. M. Epidemiology of invasive cutaneous melanoma. Ann Oncol 2009;20 Suppl 6:vi1–7.4.4. Trotter S.C., Sroa N., Winkelmann R. R. et al. A Global Review of Melanoma Follow-up Guidelines. J Clin Aesthet Dermatol 2013;6(9):18–26.Trotter S.C., Sroa N., Winkelmann R. R. et al. A Global Review of Melanoma Follow-up Guidelines. J Clin Aesthet Dermatol 2013;6(9):18–26.5.5. Chakraborty R., Wieland C. N., Comfere N. I. Molecular targeted therapies in metastatic melanoma. Pharmgenomics Pers Med 2013;6:49–56.Chakraborty R., Wieland C. N., Comfere N. I. Molecular targeted therapies in metastatic melanoma. Pharmgenomics Pers Med 2013;6:49–56.6.6. Curtin J. A., Fridlyand J., Kageshita T. et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005;353(20):2135–47.Curtin J. A., Fridlyand J., Kageshita T. et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005;353(20):2135–47.7.7. Гребенникова О. П., Прилепо В. Н. Меланома. Онкология для практикующих врачей. Под ред. С. С. Чистякова. М., 2009. С. 548–63. [Grebennikova O.P., Prilepo V.N., Melanoma. Oncology for practicing clinicians. S.S. Chistyakov (ed.). Moscow, 2009. Pp. 548–63. (In Russ.)]Гребенникова О. П., Прилепо В. Н. Меланома. Онкология для практикующих врачей. Под ред. С. С. Чистякова. М., 2009. С. 548–63. [Grebennikova O.P., Prilepo V.N., Melanoma. Oncology for practicing clinicians. S.S. Chistyakov (ed.). Moscow, 2009. Pp. 548–63. (In Russ.)]8.8. Mihajlovic M., Vlajkovic S., Jovanovic P., Stefanovic V. Primary mucosal melanomas: a comprehensive review. Int J Clin Exp Pathol 2012;5(8):739–53.Mihajlovic M., Vlajkovic S., Jovanovic P., Stefanovic V. Primary mucosal melanomas: a comprehensive review. Int J Clin Exp Pathol 2012;5(8):739–53.9.9. van den Bosch T., Kilic E., Paridaens D., de Klein A. Genetics of uveal melanoma and cutaneous melanoma: two of a kind? Dermatol Res Pract 2010;2010:360136. doi: 10.1155 / 2010 / 360136.van den Bosch T., Kilic E., Paridaens D., de Klein A. Genetics of uveal melanoma and cutaneous melanoma: two of a kind? Dermatol Res Pract 2010;2010:360136. doi: 10.1155 / 2010 / 360136.10.10. Goldstein A. M., Tucker M. A. Genetic epidemiology of cutaneous melanoma. Arch Dermatol 2001;137(11):1493–6.Goldstein A. M., Tucker M. A. Genetic epidemiology of cutaneous melanoma. Arch Dermatol 2001;137(11):1493–6.11.11. Hansson J. Familial cutaneous melanoma. Adv Exp Med Biol 2010;685:134–45.Hansson J. Familial cutaneous melanoma. Adv Exp Med Biol 2010;685:134–45.12.12. Bradford P. T., Freedman D. M., Goldstein A. M., Tucker M. A. Increased risk of second primary cancers after a diagnosis of melanoma. Arch Dermatol 2010;146(3):265–72.Bradford P. T., Freedman D. M., Goldstein A. M., Tucker M. A. Increased risk of second primary cancers after a diagnosis of melanoma. Arch Dermatol 2010;146(3):265–72.13.13. Sekulic A., Haluska P. Jr., Miller A. J. et al.; Melanoma Study Group of Mayo Clinic Cancer Center. Malignant melanoma in the 21st century: the emerging molecular landscape. Mayo Clin Proc 2008;83(7):825–46.Sekulic A., Haluska P. Jr., Miller A. J. et al.; Melanoma Study Group of Mayo Clinic Cancer Center. Malignant melanoma in the 21st century: the emerging molecular landscape. Mayo Clin Proc 2008;83(7):825–46.14.14. Hayward N. K. Genetics of melanoma predisposition. Oncogene 2003;22(20):3053–62.Hayward N. K. Genetics of melanoma predisposition. Oncogene 2003;22(20):3053–62.15.15. Bennett D. C. How to make a melanoma: what do we know of the primary clonal events? Pigment Cell Melanoma Res 2008;21(1):27–38.Bennett D. C. How to make a melanoma: what do we know of the primary clonal events? Pigment Cell Melanoma Res 2008;21(1):27–38.16.16. Bello D. M., Ariyan C. E., Carvajal R. D. Melanoma mutagenesis and aberrant cell signaling. Cancer Control 2013;20(4):261–81.Bello D. M., Ariyan C. E., Carvajal R. D. Melanoma mutagenesis and aberrant cell signaling. Cancer Control 2013;20(4):261–81.17.17. Platz A., Egyhazi S., Ringborg U., Hansson J. Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site. Mol Oncol 2008;1(4):395–405.Platz A., Egyhazi S., Ringborg U., Hansson J. Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site. Mol Oncol 2008;1(4):395–405.18.18. Helgadottir H., Höiom V., Jönsson G. et al. High risk of tobacco-related cancers in CDKN2A mutation-positive melanoma families. J Med Genet 2014;51(8):545–52.Helgadottir H., Höiom V., Jönsson G. et al. High risk of tobacco-related cancers in CDKN2A mutation-positive melanoma families. J Med Genet 2014;51(8):545–52.19.19. Bressac-de-Paillerets B., Avril M. F., Chompret A., Demenais F. Genetic and environmental factors in cutaneous malignant melanoma. Biochimie 2002;84(1):67–74.Bressac-de-Paillerets B., Avril M. F., Chompret A., Demenais F. Genetic and environmental factors in cutaneous malignant melanoma. Biochimie 2002;84(1):67–74.20.20. Fargnoli M. C., Gandini S., Peris K. et al. MC1R variants increase melanoma risk in families with CDKN2A mutations: a metaanalysis. Eur J Cancer 2010;46(8):1413–20.Fargnoli M. C., Gandini S., Peris K. et al. MC1R variants increase melanoma risk in families with CDKN2A mutations: a metaanalysis. Eur J Cancer 2010;46(8):1413–20.21.21. Kennedy C., ter Huurne J., Berkhout M. et al. Melanocortin 1 receptor (MC1R) gene variants are associated with an increased risk for cutaneous melanoma which is largely independent of skin type and hair color. J Invest Dermatol 2001;117(2):294–300.Kennedy C., ter Huurne J., Berkhout M. et al. Melanocortin 1 receptor (MC1R) gene variants are associated with an increased risk for cutaneous melanoma which is largely independent of skin type and hair color. J Invest Dermatol 2001;117(2):294–300.22.22. Palmer J. S., Duffy D. L., Box N. F. et al. Melanocortin-1 receptor polymorphisms and risk of melanoma: is the association explained solely by pigmentation phenotype? Am J Hum Genet 2000;66(1):176–86.Palmer J. S., Duffy D. L., Box N. F. et al. Melanocortin-1 receptor polymorphisms and risk of melanoma: is the association explained solely by pigmentation phenotype? Am J Hum Genet 2000;66(1):176–86.23.23. Williams P. F., Olsen C. M., Hayward N. K., Whiteman D. C. Melanocortin 1 receptor and risk of cutaneous melanoma: a meta-analysis and estimates of population burden. Int J Cancer 2011;129(7):1730–40.Williams P. F., Olsen C. M., Hayward N. K., Whiteman D. C. Melanocortin 1 receptor and risk of cutaneous melanoma: a meta-analysis and estimates of population burden. Int J Cancer 2011;129(7):1730–40.24.24. Yokoyama S., Woods S. L., Boyle G. M. et al. A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. Nature 2011;480(7375): 99–103.Yokoyama S., Woods S. L., Boyle G. M. et al. A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. Nature 2011;480(7375): 99–103.25.25. Vachtenheim J., Borovanský J. Microphthalmia transcription factor: a specific marker for alignant melanoma. Prague Med Rep 2004;105(3):318–24.Vachtenheim J., Borovanský J. Microphthalmia transcription factor: a specific marker for alignant melanoma. Prague Med Rep 2004;105(3):318–24.26.26. Bertolotto C., Lesueur F., Giuliano S. et al. A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature 2011;480(7375):94–8.Bertolotto C., Lesueur F., Giuliano S. et al. A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature 2011;480(7375):94–8.27.27. Guo R., Franco-Palacios M., Russell M. et al. Micropthalmia transcription factor (MITF) as a diagnostic marker for metastatic melanomas negative for other melanoma markers. Int J Clin Exp Pathol 2013;6(8):1658–64.Guo R., Franco-Palacios M., Russell M. et al. Micropthalmia transcription factor (MITF) as a diagnostic marker for metastatic melanomas negative for other melanoma markers. Int J Clin Exp Pathol 2013;6(8):1658–64.28.28. Shen J., Lei Q., Chen X. et al. Diagnostic performance of micropthalmia transcription factor for melanoma: a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci 2014;18(6):798–805.Shen J., Lei Q., Chen X. et al. Diagnostic performance of micropthalmia transcription factor for melanoma: a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci 2014;18(6):798–805.29.29. Berger M., Hodis E., Heffernan T. et al. Melanoma genome sequencing reveals frequent PREX2 mutations. Nature 2012;485(7399):502–6.Berger M., Hodis E., Heffernan T. et al. Melanoma genome sequencing reveals frequent PREX2 mutations. Nature 2012;485(7399):502–6.30.30. Pleasance E. D., Cheetham R. K., Stephens P. J. et al. A comprehensive catalogue of omatic mutations from a human cancer genome. Nature 2010;463(7278):191–6.Pleasance E. D., Cheetham R. K., Stephens P. J. et al. A comprehensive catalogue of omatic mutations from a human cancer genome. Nature 2010;463(7278):191–6.31.31. Hodis E., Watson I. R., Kryukov G. V. et al. A landscape of driver mutations in melanoma. Cell 2012;150(2):251–63.Hodis E., Watson I. R., Kryukov G. V. et al. A landscape of driver mutations in melanoma. Cell 2012;150(2):251–63.32.32. Chapman P. B., Hauschild A., Robert C. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364(26):2507–16.Chapman P. B., Hauschild A., Robert C. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364(26):2507–16.33.33. Lázár V., Ecsedi S., Vízkeleti L. et al. Marked genetic differences between BRAF and NRAS mutated primary melanomas as revealed by array comparative genomic hybridization. Melanoma Res 2012;22(3): 202–14.Lázár V., Ecsedi S., Vízkeleti L. et al. Marked genetic differences between BRAF and NRAS mutated primary melanomas as revealed by array comparative genomic hybridization. Melanoma Res 2012;22(3): 202–14.34.34. Smalley K. S., Sondak V. K., Weber J. S. C-KIT signaling as the driving oncogenic event in sub-groups of melanomas. Histol Histopathol 2009;24(5):643–50.Smalley K. S., Sondak V. K., Weber J. S. C-KIT signaling as the driving oncogenic event in sub-groups of melanomas. Histol Histopathol 2009;24(5):643–50.35.35. Miller A. J., Mihm M. C. Melanoma. N Engl J Med 2006;355(1):51–65.Miller A. J., Mihm M. C. Melanoma. N Engl J Med 2006;355(1):51–65.36.36. Berger M. F., Garraway L. A. Applications of genomics in melanoma oncogene discovery. Hematol Oncol Clin North Am 2009;23(3):397–414.Berger M. F., Garraway L. A. Applications of genomics in melanoma oncogene discovery. Hematol Oncol Clin North Am 2009;23(3):397–414.37.37. Long G. V., Menzies A. M., Nargial A. M. et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 2011;29(10):1239–46.Long G. V., Menzies A. M., Nargial A. M. et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 2011;29(10):1239–46.38.38. Rajakulendran T., Sahmi M., Lefrançois M. et al. A dimerization-dependent mechanism drives RAF catalytic activation. Nature 2009;461(7263):542–5.Rajakulendran T., Sahmi M., Lefrançois M. et al. A dimerization-dependent mechanism drives RAF catalytic activation. Nature 2009;461(7263):542–5.39.39. Davies H., Bignell G. R., Cox C. et al. Mutations of the BRAF gene in human cancer. Nature 2002;417(6892):949–54.Davies H., Bignell G. R., Cox C. et al. Mutations of the BRAF gene in human cancer. Nature 2002;417(6892):949–54.40.40. Lovly C. M., Dablman K. B., Fobn L. E. et al. Routine multiplex mutational profiling of melanomas enables enrollment in genotype – driven therapeutic trials. PLoS One 2012;7(4):e35309.Lovly C. M., Dablman K. B., Fobn L. E. et al. Routine multiplex mutational profiling of melanomas enables enrollment in genotype – driven therapeutic trials. PLoS One 2012;7(4):e35309.41.41. Lin K., Baritaki S., Militello L. et al. The role of B-RAF mutations in melanoma and the induction of EMT via dysregulation of the NF-KB / Snail / RKIP / PTEN circuit. Genes Cancer 2010;1(5):409–20.Lin K., Baritaki S., Militello L. et al. The role of B-RAF mutations in melanoma and the induction of EMT via dysregulation of the NF-KB / Snail / RKIP / PTEN circuit. Genes Cancer 2010;1(5):409–20.42.42. Wan P. T., Garnett M. J., Roe S. M. et al. Mechanism of activation of the RAF–ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004;16(6):855–67.Wan P. T., Garnett M. J., Roe S. M. et al. Mechanism of activation of the RAF–ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004;16(6):855–67.43.43. Davies M. A., Samuels Y. Analysis of the genome to personalize therapy for melanoma. Oncogene 2010;29(41):5545–55.Davies M. A., Samuels Y. Analysis of the genome to personalize therapy for melanoma. Oncogene 2010;29(41):5545–55.44.44. Hutchinson K. E., Lipson D., Stephens P. J. et al. BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition. Clin Cancer Res 2013;19(24):6696–702.Hutchinson K. E., Lipson D., Stephens P. J. et al. BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition. Clin Cancer Res 2013;19(24):6696–702.45.45. Fedorenko I. V., Gibney G. T., Keiran S. M. NRAS mutant melanoma: biological behavior and future strategies for therapeutic management. Oncogene 2013;32(25):3009–18.Fedorenko I. V., Gibney G. T., Keiran S. M. NRAS mutant melanoma: biological behavior and future strategies for therapeutic management. Oncogene 2013;32(25):3009–18.46.46. Kelleher F. C., McArthur G. A. Targeting NRAS in melanoma. Cancer J 2012;18(2):132–6.Kelleher F. C., McArthur G. A. Targeting NRAS in melanoma. Cancer J 2012;18(2):132–6.47.47. Ross A. L., Sanchez M. I., Grichnik J. M. Molecular nevogenesis. Dermatol Res Pract 2011;2011:463184. doi: 10.1155 / 2011 / 463184.Ross A. L., Sanchez M. I., Grichnik J. M. Molecular nevogenesis. Dermatol Res Pract 2011;2011:463184. doi: 10.1155 / 2011 / 463184.48.48. Chraybi M., Alsamad I. A., Copie-Bergman C. et al. Oncogene abnormalities in a series of primary melanomas of the sinonasal tract: NRAS mutations and cyclin D1 amplification are more frequent than KIT or BRAF mutations. Hum Pathol 2013;44(9):1902–11.Chraybi M., Alsamad I. A., Copie-Bergman C. et al. Oncogene abnormalities in a series of primary melanomas of the sinonasal tract: NRAS mutations and cyclin D1 amplification are more frequent than KIT or BRAF mutations. Hum Pathol 2013;44(9):1902–11.49.49. Zebary A., Jangard M., Omholt K. et al. KIT, NRAS and BRAF mutations in sinonasal mucosal melanoma: a study of 56 cases. Br J Cancer 2013;109(3):559–64.Zebary A., Jangard M., Omholt K. et al. KIT, NRAS and BRAF mutations in sinonasal mucosal melanoma: a study of 56 cases. Br J Cancer 2013;109(3):559–64.50.50. Dumaz N. Mechanism of RAF isoform switching induced by oncogenic RAS in melanoma. Small GTPases 2011;2(5):289–92.Dumaz N. Mechanism of RAF isoform switching induced by oncogenic RAS in melanoma. Small GTPases 2011;2(5):289–92.51.51. Chudnovsky Y., Adams A. E., Robbins P. B. et al. Use of human tissue to assess the ncogenic activity of melanoma-associated mutations. Nat Genet 2005;37(7):745–9.Chudnovsky Y., Adams A. E., Robbins P. B. et al. Use of human tissue to assess the ncogenic activity of melanoma-associated mutations. Nat Genet 2005;37(7):745–9.52.52. Michaloglou C., Vredeveld L. C., Soengas M. S. et al. BRAFE600‑associated senescence-like cell cycle arrest of human naevi. Nature 2005;436(7051):720–4.Michaloglou C., Vredeveld L. C., Soengas M. S. et al. BRAFE600‑associated senescence-like cell cycle arrest of human naevi. Nature 2005;436(7051):720–4.53.53. Jakob J. A., Bassett R. L. Jr., Ng C. S. et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 2012;118(16):4014–23.Jakob J. A., Bassett R. L. Jr., Ng C. S. et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 2012;118(16):4014–23.54.54. Stahl J. M., Sharma A., Cheung M. et al. Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res 2004;64(19):7002–10.Stahl J. M., Sharma A., Cheung M. et al. Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res 2004;64(19):7002–10.55.55. Stahl J. M., Cheung M., Sharma A. et al. Loss of PTEN promotes tumor development in malignant melanoma. Cancer Res 2003;63(11):2881–90.Stahl J. M., Cheung M., Sharma A. et al. Loss of PTEN promotes tumor development in malignant melanoma. Cancer Res 2003;63(11):2881–90.56.56. Davies M. A., Stemke-Hale K., Tellez C. et al. A novel AKT3 mutation in melanoma tumours and cell lines. Br J Cancer 2008;99(8):1265–8.Davies M. A., Stemke-Hale K., Tellez C. et al. A novel AKT3 mutation in melanoma tumours and cell lines. Br J Cancer 2008;99(8):1265–8.57.57. Tsao H., Mihm M. C. Jr., Sheehan C. PTEN expression in normal skin, acquired melanocytic nevi, and cutaneous melanoma. J Am Acad Dermatol 2003;49(5):865–72.Tsao H., Mihm M. C. Jr., Sheehan C. PTEN expression in normal skin, acquired melanocytic nevi, and cutaneous melanoma. J Am Acad Dermatol 2003;49(5):865–72.58.58. Wu H., Goel V., Haluska F. G. PTEN signaling pathways in melanoma. Oncogene 2003;22(20):3113–22.Wu H., Goel V., Haluska F. G. PTEN signaling pathways in melanoma. Oncogene 2003;22(20):3113–22.59.59. Dadras S. S. Molecular diagnostics in melanoma: current status and perspectives. Arch Pathol Lab Med 2011;135(7):860–9.Dadras S. S. Molecular diagnostics in melanoma: current status and perspectives. Arch Pathol Lab Med 2011;135(7):860–9.60.60. Tschandi P., Berghoff A. S., Preusser M. et al. NRAS and BRAF mutations in melanoma- associated nevi and uninvolved nevi. PLoS One 2013;8(7):e69639.Tschandi P., Berghoff A. S., Preusser M. et al. NRAS and BRAF mutations in melanoma- associated nevi and uninvolved nevi. PLoS One 2013;8(7):e69639.61.61. Vredeveld L. C., Possik P. A., Smit M. A. et al. Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis. Genes Dev 2012;26(10):1055–69.Vredeveld L. C., Possik P. A., Smit M. A. et al. Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis. Genes Dev 2012;26(10):1055–69.62.62. Dai D. L., Martinka M., Li G. Prognostic significance of activated Akt expression in melanoma: A clinicopathologic study of 292 cases. J Clin Oncol 2005;23(7):1473–82.Dai D. L., Martinka M., Li G. Prognostic significance of activated Akt expression in melanoma: A clinicopathologic study of 292 cases. J Clin Oncol 2005;23(7):1473–82.63.63. Janku F., Novotny J., Julis I. et al. KIT receptor is expressed in more than 50 % of early-stage malignant melanoma: a retrospective study of 261 patients. Melanoma Res 2005;15(4):251–6.Janku F., Novotny J., Julis I. et al. KIT receptor is expressed in more than 50 % of early-stage malignant melanoma: a retrospective study of 261 patients. Melanoma Res 2005;15(4):251–6.64.64. Mobley A. K., Braeuer R. R., Kamiya T. et al. Driving transcriptional regulators in melanoma metastasis. Cancer Metastasis Rev 2012;31(3–4):621–32.Mobley A. K., Braeuer R. R., Kamiya T. et al. Driving transcriptional regulators in melanoma metastasis. Cancer Metastasis Rev 2012;31(3–4):621–32.65.65. Willmore-Payne C., Holden J. A., Hirschowitz S., Layfield L. J. BRAF and c-kit gene copy number in mutation positive malignant melanoma. Hum Pathol 2006;37(5):520–7.Willmore-Payne C., Holden J. A., Hirschowitz S., Layfield L. J. BRAF and c-kit gene copy number in mutation positive malignant melanoma. Hum Pathol 2006;37(5):520–7.66.66. Curtin J. A., Busam K., Pinkel D., Bastian B. C. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006;24(26):4340–6.Curtin J. A., Busam K., Pinkel D., Bastian B. C. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006;24(26):4340–6.67.67. Beadling C., Jacobson-Dunlop E., Hodi F. S. et al. KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res 2008;14(21):6821–8.Beadling C., Jacobson-Dunlop E., Hodi F. S. et al. KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res 2008;14(21):6821–8.68.68. Dai B., Cai X., Kong Y. Y. et al. Analysis of KIT expression and gene mutation in human acral melanoma: with a comparison between primary tumors and corresponding metastases / recurrences. Hum Pathol 2013;44(8):1472–8.Dai B., Cai X., Kong Y. Y. et al. Analysis of KIT expression and gene mutation in human acral melanoma: with a comparison between primary tumors and corresponding metastases / recurrences. Hum Pathol 2013;44(8):1472–8.69.69. Antonescu C. R., Busam K. J., Francone T. D. et al. L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition. Int J Cancer 2007;121(2):257–64.Antonescu C. R., Busam K. J., Francone T. D. et al. L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition. Int J Cancer 2007;121(2):257–64.70.70. Yun J., Lee J., Jang J. et al. KIT amplification and gene mutations in acral / mucosal melanoma in Korea. APMIS 2011;119(6):330–5.Yun J., Lee J., Jang J. et al. KIT amplification and gene mutations in acral / mucosal melanoma in Korea. APMIS 2011;119(6):330–5.71.71. Allegra M., Giacchero D., Segalen C., Dumaz N. A new KIT mutation (N505I) in acral melanoma confers constitutive signaling, favors tumorigenic properties, and is sensitive to imatinib. J Invest Dermatol 2014;134(5):1473–6.Allegra M., Giacchero D., Segalen C., Dumaz N. A new KIT mutation (N505I) in acral melanoma confers constitutive signaling, favors tumorigenic properties, and is sensitive to imatinib. J Invest Dermatol 2014;134(5):1473–6.72.72. Мазуренко Н. Н., Цыганова И. В., Герасимова Н. П. и др. Гетерогенность мишеней таргетной терапии различных субтипов меланомы. Евразийский онкологический журнал 2013;3(03):106.Мазуренко Н. Н., Цыганова И. В., Герасимова Н. П. и др. Гетерогенность мишеней таргетной терапии различных субтипов меланомы. Евразийский онкологический журнал 2013;3(03):106.73.[Mazurenko N.N., Tsyganova I.V., Gerasimova N.P. et al. Heterogeneity of targeted therapy argets of different subtypes of melanoma. Evraziyskiy onkologicheskiy zhurnal = Eurasian Oncology Journal 2013;3(03):106. (In Russ.)][Mazurenko N.N., Tsyganova I.V., Gerasimova N.P. et al. Heterogeneity of targeted therapy argets of different subtypes of melanoma. Evraziyskiy onkologicheskiy zhurnal = Eurasian Oncology Journal 2013;3(03):106. (In Russ.)]74.73. Mazurenko N. N., Tsyganova I. V., Lushnikova A. A. et al. Spectrum of driver mutations in melanoma subtypes. Drug Metabol Drug Interact 2014;29(3):75.Mazurenko N. N., Tsyganova I. V., Lushnikova A. A. et al. Spectrum of driver mutations in melanoma subtypes. Drug Metabol Drug Interact 2014;29(3):75.75.74. Bourillon A., Hu H. H., Hetet G. et al. Genetic variation at KIT locus may predispose to melanoma. Pigment Cell Melanoma Res 2013;26(1):88–96.Bourillon A., Hu H. H., Hetet G. et al. Genetic variation at KIT locus may predispose to melanoma. Pigment Cell Melanoma Res 2013;26(1):88–96.76.75. Sparrow L. E., Soong R., Dawkins H. J. et al. p53 gene mutation and expression in naevi and melanomas. Melanoma Res 1995;5(2):93–100.Sparrow L. E., Soong R., Dawkins H. J. et al. p53 gene mutation and expression in naevi and melanomas. Melanoma Res 1995;5(2):93–100.77.76. Krauthammer M., Kong Y., Ha B. H. et al. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet 2012;44(9):1006–14.Krauthammer M., Kong Y., Ha B. H. et al. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet 2012;44(9):1006–14.78.77. Xia J., Jia P., Hutchinson K. E. et al. A meta-analysis of somatic mutations from next generation sequencing of 241 melanomas: a road map for the study of genes with potential clinical relevance. Mol Cancer Ther 2014;13(7):1918–28.Xia J., Jia P., Hutchinson K. E. et al. A meta-analysis of somatic mutations from next generation sequencing of 241 melanomas: a road map for the study of genes with potential clinical relevance. Mol Cancer Ther 2014;13(7):1918–28.79.78. Демидов Л. В., Утяшев И. А., аркевич Г. Ю. Роль вемурафениба в лечении диссеминированной меланомы кожи. Современная онкология 2013;15(2):58–61. [Demidov L.V., Utyashev I.A., Kharkevich G.Yu. Role of vemurafenib in therapy of disseminated melanoma. Sovremennaya onkologiya = Modern Oncology 2013;15(2):58–61. (In Russ.)]Демидов Л. В., Утяшев И. А., аркевич Г. Ю. Роль вемурафениба в лечении диссеминированной меланомы кожи. Современная онкология 2013;15(2):58–61. [Demidov L.V., Utyashev I.A., Kharkevich G.Yu. Role of vemurafenib in therapy of disseminated melanoma. Sovremennaya onkologiya = Modern Oncology 2013;15(2):58–61. (In Russ.)]80.79. Wellbrock C., Hurlstone A. BRAF as therapeutic target in melanoma. Biochem Pharmacol 2010;80(5):561–7.Wellbrock C., Hurlstone A. BRAF as therapeutic target in melanoma. Biochem Pharmacol 2010;80(5):561–7.81.80. Flaherty K. T., Puzanov I., Kim K. B. et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010;363(9):809–19.Flaherty K. T., Puzanov I., Kim K. B. et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010;363(9):809–19.82.81. Hauschild A., Grob J. J., Demidov L. V. et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, openlabel, phase 3 randomised controlled trial. Lancet 2012;380(9839):358–65.Hauschild A., Grob J. J., Demidov L. V. et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, openlabel, phase 3 randomised controlled trial. Lancet 2012;380(9839):358–65.83.82. Kirkwood J. M., Long G. V., Trefzer U. et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 2012;13(11):1087–95.Kirkwood J. M., Long G. V., Trefzer U. et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 2012;13(11):1087–95.84.83. Trunzer K., Pavlick A. C., Schuchter L. et al. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol 2013;31(14):1767–74.Trunzer K., Pavlick A. C., Schuchter L. et al. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol 2013;31(14):1767–74.85.84. Van Allen E. M., Wagle N., Sucker A. et al.; Dermatologic Cooperative Oncology Group of Germany(DeCOG). The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov 2014;4(1):94–109.Van Allen E. M., Wagle N., Sucker A. et al.; Dermatologic Cooperative Oncology Group of Germany(DeCOG). The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov 2014;4(1):94–109.86.85. Poulikakos P. I., Persaud Y., Janakiraman M. et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 2011;480(7377):387–90.Poulikakos P. I., Persaud Y., Janakiraman M. et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 2011;480(7377):387–90.87.86. Akinleye A., Furqan M., Mukhi N. et al. MEK and the inhibitors: from bench to bedside. J Hematol Oncol 2013;6:27. doi: 10.1186 / 1756‑8722‑6‑27.Akinleye A., Furqan M., Mukhi N. et al. MEK and the inhibitors: from bench to bedside. J Hematol Oncol 2013;6:27. doi: 10.1186 / 1756‑8722‑6‑27.88.87. Voskoboynik M., Arkenau H. T. Combination therapies for the treatment of advanced melanoma: a review of current evidence. Biochem Res Int 2014;2014:307059. doi: 10.1155 / 2014 / 307059.Voskoboynik M., Arkenau H. T. Combination therapies for the treatment of advanced melanoma: a review of current evidence. Biochem Res Int 2014;2014:307059. doi: 10.1155 / 2014 / 307059.89.88. Dahlman K. B., Xia J., Hutchinson K. et al. BRAF (L597) mutations in melanoma are associated with sensitivity to MEK inhibitors. Cancer Discov 2012;2(9):791–7.Dahlman K. B., Xia J., Hutchinson K. et al. BRAF (L597) mutations in melanoma are associated with sensitivity to MEK inhibitors. Cancer Discov 2012;2(9):791–7.90.89. Bowyer S. E., Rao A. D., Lyle M. et al. Activity of trametinib in K601E and L597Q BRAF mutation-positive metastatic melanoma. Melanoma Res 2014;24(5):504–8.Bowyer S. E., Rao A. D., Lyle M. et al. Activity of trametinib in K601E and L597Q BRAF mutation-positive metastatic melanoma. Melanoma Res 2014;24(5):504–8.91.90. Johnson D. B., Flaherty K. T., Weber J. S. et al. Combined BRAF (Dabrafenib) and MEK Inhibition (Trametinib) in patients with BRAF V600‑mutant melanoma experiencing progression with single-agent BRAF inhibitor. J Clin Oncol 2014. pii: JCO. 2014.57.3535.Johnson D. B., Flaherty K. T., Weber J. S. et al. Combined BRAF (Dabrafenib) and MEK Inhibition (Trametinib) in patients with BRAF V600‑mutant melanoma experiencing progression with single-agent BRAF inhibitor. J Clin Oncol 2014. pii: JCO. 2014.57.3535.